Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 265-272

  Yeh, Rosa F ^a,b   Pawlikowski, Matthew A ^a   Blough, David K ^c,d   McDonald, George B ^b,d   O'Donnell, Paul V ^b,d   Rezvani, Andrew ^b,d   Deeg, H Joachim ^b,d   McCune, Jeannine S ^b,c,d  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Public Health Sciences   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Busulfan; Hematopoietic cell transplant; Personalized medicine; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MONITORING; FEASIBILITY STUDY; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84855572744     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.06.013     Document Type: Article

References (24)

1. McCune J.S., Gibbs J.P., Slattery J.T. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet 2000, 39:155-165.
2. McCune J.S., Holmberg L.A. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol 2009, 5:957-969.
3. Slattery J.T., Risler L.J. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998, 20:543-549.
4. Kletzel M., Jacobsohn D., Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:472-479.
5. Pidala J., Kim J., Anasetti C., et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010, 3:36.
6. Pai M.P., Paloucek F.P. The origin of the " ideal" body weight equations. Ann Pharmacother 2000, 34:1066-1069.
7. Nguyen L., Leger F., Lennon S., Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006, 57:191-198.
8. Salinger D.H., Vicini P., Blough D.K., O'Donnell P.V., Pawlikowski M.A., McCune J.S. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol 2010, 50:1292-1300.
9. Gibbs J.P., Gooley T., Corneau B., et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999, 93:4436-4440.
10. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
11. Rezvani A, Storer B, McCune J, Batchelder A, McDonald G, Deeg H. Low toxicity and non-relapse mortality with reversed-order conditioning (cyclophosphamide followed by busulfan) in allogeneic hematopoietic cell transplantation. Poster Presentation at American Society of Hematology, 2009. New Orleans, LA. Abstract #1175.
12. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
13. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003, 102:820-826.
14. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
15. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
16. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
17. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
18. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1095-1105.
19. Almog S., Kurnik D., Shimoni A., et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant 2011, 17:117-123.
20. Bleyzac N., Souillet G., Magron P., et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001, 28:743-751.
21. Bertholle-Bonnet V., Bleyzac N., Galambrun C., et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit 2007, 29:177-184.
22. Salinger D.H., McCune J.S., Ren A.G., et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res 2006, 12:4888-4898.
23. McCune J.S., Batchelder A., Guthrie K.A., et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009, 85:615-622.
24. Le Meur Y., Buchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496-2503.